Skip to main content

Find Clinical Trials

Home
Conditions
Neuroendocrine Tumors

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

258 public trials 70 recruiting studies

Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Recruiting

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

NCT07165132

Conditions: Adenocarcinoma, Adenoma, Adenoma, Islet Cell, +24 more
Locations: Research Facility Iowa City, Iowa, United States

Research Facility Lexington, Kentucky, United States

Research Facility St Louis, Missouri, United States

Research Facility St Louis, Missouri, United States

View Trial Details

Recruiting

Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

NCT04104529

Conditions: Endocrine Gland Neoplasms, Endocrine System Diseases, Genital Diseases, +19 more
Locations: Hopital Haut Lévêque Bordeaux, Aquitaine, France

Hôpital LaTimone Marseille, Bouches Du Rhône, France

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Montpellier, France

Institut Universitaire du Cancer de Toulouse Toulouse, France

View Trial Details

Recruiting

CapTemY90 for Grade 2/3 NET Liver Metastases

NCT04339036

Conditions: Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +4 more
Locations: UC San Diego La Jolla, California, United States

University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States

Roswell Park Comprehensive Cancer Center Buffalo, New York, United States

University of Pennsylvania Philadelphia, Pennsylvania, United States

View Trial Details

Recruiting

Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET

NCT04954820

Conditions: Disease Attributes, Disease Progression, Intestinal Well Differentiated Endocrine Tumor, +9 more
Locations: Institut de Cancérologie de l'Ouest Site d'Angers Angers, France

Institut Bergonié Bordeaux, France

CHRU Morvan Brest, France

Hospices civils de LYON - GHE Bron, France

View all 28 locations

View Trial Details

Recruiting

Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation

NCT06430021

Conditions: MEN1 Mutation, Neoplasms, Neoplasms by Histologic Type, +4 more
Locations: Chu Dijon Bourgogne Dijon, France

View Trial Details

Recruiting

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

NCT06263088

Conditions: Anal Cancer, Anus Diseases, Anus Neoplasms, +40 more
Locations: University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Recruiting

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN

NCT06735560

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +16 more
Locations: CHU de Nantes Nantes, France

AP-HP - Site de Beaujon Paris, France

View Trial Details

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

NCT05918302

Conditions: Hemic and Lymphatic Diseases, Lung Neuroendocrine Neoplasm, Lymphatic Diseases, +9 more
Locations: Antwerp University Hospital (UZA) Edegem, Belgium

UCL Saint-Luc Brussels, Belgium

CHU Liège Liège, Belgium

Hospital Center University Dijon Bourgogne (CHU Bourgogne) Dijon, France

View all 27 locations

View Trial Details

Recruiting

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

NCT04888481

Conditions: Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +3 more
Locations: University of Alberta Edmonton, Alberta, Canada

View Trial Details

Recruiting

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

NCT06889493

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Neuroendocrine, +8 more
Locations: University of Miami Miami, Florida, United States

View Trial Details